Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
467-01-007 ISMRM Abstract

Distortion-corrected thoracic diffusion-weighted MRI to enable treatment response monitoring in malignant mesothelioma

Primary: Body - Chest/Thorax
Secondary: Acquisition & Reconstruction - Artifacts and Correction Strategies
467-01-007 · Quantitative Imaging Beyond the CNS · Tuesday, 12 May, 8:20 AM–9:15 AM · Digital Posters Row H
Keywords: Analysis/Processing Thorax Treatment Response Distortion correction Body DWI
Accepted
Sam Keaveney 1,2, Georgina Hopkinson1, Antonio Candito1,2, Matthew D Blackledge2, Cara Owens1, Anna Minchom3,4, Nina Tunariu1,2, Jessica M Winfield1,2
1MRI Unit, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton, United Kingdom
3Lung Unit, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
4Drug Development Unit, The Institute of Cancer Research, Sutton, United Kingdom
Presenting Author: Sam Keaveney

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Chu, Q., Perrone, F., Greillier, L., Tu, W., et al., Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. The Lancet, 2023. 402(10419): p. 2295-2306 doi:10.1016/S0140-6736(23)01613-6. [doi]
2. Baas, P., Scherpereel, A., Nowak, A.K., Fujimoto, N., et al., First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet, 2021. 397(10272): p. 375-386 doi:10.1016/S0140-6736(20)32714-8. [doi]
3. Byrne, M. and Nowak, A.K., Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Annals of Oncology, 2004. 15(2): p. 257-260 doi:10.1093/annonc/mdh059. [doi]
4. Cheng, L., Tunariu, N., Collins, D.J., Blackledge, M.D., et al., Response evaluation in mesothelioma: beyond RECIST. Lung Cancer, 2015. 90(3): p. 433-441 doi:10.1016/j.lungcan.2015.08.012. [doi]
5. Curcean, S., Cheng, L., Picchia, S., Tunariu, N., et al., Early response to chemotherapy in malignant pleural mesothelioma evaluated using diffusion-weighted magnetic resonance imaging: initial observations. JTO Clinical and Research Reports, 2021. 2(12): p. 100253 doi:10.1016/j.jtocrr.2021.100253. [doi]
6. Armato III, S.G., Blyth, K.G., Keating, J.J., Katz, S., et al., Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group. Lung cancer, 2016. 101: p. 48-58 doi:10.1016/j.lungcan.2016.09.003. [doi]
7. Andersson, J.L., Skare, S., and Ashburner, J., How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging. Neuroimage, 2003. 20(2): p. 870-888 doi:10.1016/S1053-8119(03)00336-7. [doi]
8. Jenkinson, M., Beckmann, C.F., Behrens, T.E., Woolrich, M.W., et al., FSL. Neuroimage, 2012. 62(2): p. 782-790 doi:10.1016/j.neuroimage.2011.09.015. [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/467-01-007